

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61M 29/00, A61F 2/06, B29C 67/02		A1	(11) International Publication Number: WO 96/00103 (43) International Publication Date: 4 January 1996 (04.01.96)
(21) International Application Number: PCT/US95/07326		(1) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 7 June 1995 (07.06.95)		Published <i>With international search report.</i>	
(30) Priority Data: 08/265,794 27 June 1994 (27.06.94) US			
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/265,794 (CON) 27 June 1994 (27.06.94)			
(71) Applicant (for all designated States except US): ENDOMED, INC. [US/US]; Suite 123, 1430 E. Missouri Avenue, Phoenix, AZ 85014 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): COLONE, William, M. [US/US]; 3065 E. Dry Creek Road, Phoenix, AZ 85048 (US).			
(74) Agent: WILLIAMS, John, N.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).			
(54) Title: RADIALLY EXPANDABLE POLYTETRAFLUOROETHYLENE AND EXPANDABLE ENDOVASCULAR STENTS FORMED THEREWITH			
(57) Abstract			
<p>Extruded, stretched, and sintered tubular PTFE materials (50), which have been radially dilated and resintered, are produced which are suited for use in the medical field, e.g., as liners and covers with support structures (52) for expandable endovascular stents (48). The PTFE materials have an unusually low REC (Radial Expansion Coefficient) and RER (Radial Expansion Ratio), permitting thin-walled PTFE tubes to expand about 50 % to 400 %, or more, before the decline in tensile strength. Tube-form medical implants comprising such PTFE material, methods for making such implants, and endovascular stents formed with such implants are described.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

RADially EXPANDABLE POLYTETRAFLUOROETHYLENE AND
EXPANDABLE ENDOVASCULAR STENTS FORMED THEREWITH

This invention relates to polytetrafluoroethylene

5 (hereinafter PTFE) materials which, after being radially expanded, retain their the structural integrity. More particularly, the invention relates to extruded, stretched, sintered tubular PTFE materials suited for use in the medical field as liners and covers for expandable
10 stents.

The use of expandable endovascular stents to open and support aortic blood vessels is well known in the art. Such stents, which are typically made from stainless steel, are thrombogenic and tend to occlude due
15 to growth of tissue through the stent into the blood vessel. The length of such stents is also limited because of their rigidity. Consequently, liners and covers have been sought for use in conjunction with metallic stents in order to shield the stent and to
20 extend the length of anatomy which can be treated with the stent. The development of acceptable stent liners or covers has been slow because the liners or covers preferably must (1) expand with the stent, (2) be non-thrombogenic, (3) be biocompatible, (4) be inert, (5)
25 have a low profile with the ability to expand up to about four times its original dimension, (6) be expandable at low pressures of less than five to ten atmospheres to reduce the risk of injury to the patient, (7) retain its physical properties and structural strength after being
30 expanded, (8) generally not alter its length after being expanded, (9) be impervious to blood at physiological pressures, (10) conform to host anatomy when expanded, (11) resist the growth of bodily tissue therethrough, (12) be able to carry radiopaque markings for location
35 during fluoroscopy.

- 2 -

Paste-formed, extruded tubular PTFE products are well known, as are paste extrusion and paste forming manufacturing processes for producing such products. During such manufacturing processes, a PTFE resin is 5 mixed with a liquid lubricant. A preformed resin/lubricant charge is then produced and extruded through an annular orifice to produce an unsintered PTFE tube. The extruded tube is heated to remove the lubricant and produce a porous, unsintered PTFE tube.

10 The tube typically has a density of from 1.5 to about 1.75 gm/cc and accompanying porosity of 39% to 26%. If the unsintered tube is sintered by heating the tube to a temperature above its crystalline melting temperature, a nonporous tube results. See U.S. Patent Nos. 3,953,566, 15 3,962,153, 4,110,392, 4,177,390, 4,283,448, 4,385,093, 4,478,665, 4,482,516, 4,877,661, and 5,026,513.

In the medical field, PTFE products are used as replacement veins and arteries. PTFE is inert, is non-thrombogenic, and has other characteristics desirable for 20 a stent cover or liner. Commercially available PTFE medical tubular products have, however, significant radial strength and are not readily dilated. Conventional PTFE tubes typically have a high radial strength and rapidly lose their tensile strength and 25 become weak and thin after being dilated by only small amounts.

Accordingly, it would be highly desirable to provide improved PTFE products which can be readily expanded and which, after being expanded, substantially 30 retain their tensile strength and other physical properties which make the use of PTFE in the body desirable.

Summary of the Invention

I have discovered new PTFE products and a process 35 and composition for producing the same. The new PTFE

Best Available Copy

- 3 -

products can be significantly expanded to configurations which retain their structural integrity and which substantially retain their tensile strength and other desirable physical properties. As discussed in detail in 5 the examples below, the new PTFE products have an unusually low REC (Radial Expansion Coefficient) and RER (Radial Expansion Ratio), permitting thin-walled PTFE tubes to expand about 50% to 400%, or more, before the tubes lose their structural integrity and suffer a rapid 10 decline in tensile strength. The new PTFE products can also be pre-dilated to insure that an RER value equal to one will be achieved.

In one aspect, the invention features a tube-form medical implant of porous material comprising crystalline 15 polytetrafluoroethylene (PTFE) polymer, which material has a microstructure of nodes interconnected by fibrils in the form of a PTFE tube in a pre-dilated and contracted diameter state as a result of radial expansion of a longitudinally expanded, sintered PTFE tube, 20 followed by contraction produced by re-sintering, the tube-form implant being expandable in use from the contracted diameter to a substantially larger implantation diameter by application of radial force.

In another aspect, the invention features a method 25 for producing a porous tube consisting essentially of highly crystalline polytetrafluoroethylene polymer, comprising the steps of: (a) extruding a lubricant/polytetrafluoroethylene resin blend to form a tubing having a longitudinal axis, a primary inner 30 diameter, and a primary length; (b) heating the tubing to remove the lubricant; (c) stretching the tubing along the longitudinal axis to produce an elongated tubing having a secondary length greater than the primary length; (d) sintering the elongated tubing to produce a sintered 35 tubing; (e) radially expanding the sintered tubing to

- 4 -

produce radially expanded tubing have an expanded inner diameter greater than the primary inner diameter; and (f) sintering the radially expanded tubing to contract the radially expanded tubing.

- 5 In another aspect, the invention features a method for producing a porous tube consisting essentially of highly crystalline polytetrafluoroethylene polymer comprising the steps of: (a) extruding a lubricant/polytetrafluoro-ethylene resin blend to form a
- 10 tubing having a longitudinal axis, a primary inner diameter, and a primary length; (b) heating the tubing to remove the lubricant; (c) stretching the tubing along the longitudinal axis to produce an elongated tubing having a secondary length greater than the primary length; (d)
- 15 restraining the elongate tubing to prevent the elongate tubing from longitudinally contracting during sintering; (e) sintering the elongated tubing to produce a sintered tubing having a length substantially equivalent to the secondary length; (f) radially expanding the sintered
- 20 tubing to produce radially expanded tubing have an expanded inner diameter greater than the primary inner diameter; and (g) sintering the radially expanded tubing to contract the radially expanded tubing and produce a tubing having an inner diameter substantially equivalent
- 25 to the primary inner diameter.

The sintered radially expanded tubing may be longitudinally stretched after step (g). The ends of the radially expanded tubing may be restrained, at a step between steps (f) and (g), to maintain the length of the

- 30 radially expanded tubing when the radially expanded tubing is sintered.

In another aspect, the invention features an expandable tubular medical implant comprising porous material of crystalline polytetrafluoroethylene polymer

- 35 having a microstructure of nodes interconnected by

- 5 -

fibrils, the tubular implant being permanently, radially expandable from a small delivery diameter, which is of low profile suitable for delivery to an implantation site inside a blood vessel, to a more than 50% larger 5 implantation diameter, which is suitable for implantation inside a blood vessel, by application of outward radial force, the tubular medical implant, after expansion to the implantation diameter, substantially retaining its expanded size, tensile strength, and structural integrity 10 so that increase in the outward radial force is required before further radial expansion can occur.

In yet another aspect, the invention features a readily dilatable tube having a low profile delivery diameter, the tube constructed as a tubular implant for 15 use in concentric relationship with an expandable stent, the tube, upon expansion by more than 50% to an implantation diameter, retaining structural integrity and substantial strength, the tube comprising a tube of expanded polytetrafluoroethylene (PTFE) in a pre-dilated 20 and contracted diameter state as a result of radial expansion of a longitudinally expanded, sintered PTFE tube, followed by contraction produced by re-sintering.

In a further aspect, the invention features an expandable endovascular stent having a contracted 25 diameter state with an outer diameter suitable for delivery through the vasculature of a patient to a desired site and an expanded diameter state with an outer diameter suitable for supporting a blood vessel at the desired site; the stent comprising: a tubular medical 30 implant, in accordance with one of the inventive aspects described above, having an interior wall surface and an exterior wall surface; and at least one tubular, radially expandable support structure coupled to the tubular medical implant, the support structure having an interior 35 wall surface and an exterior wall surface.

- 6 -

Embodiments may include one or more of the following features. The implant is preferably formed from an extruded tube having an original inner diameter, in which the pre-dilation increased the inner diameter to 5 at least two to at least five times the original inner diameter. The tube-form implant preferably has a Radial Expansion Coefficient (REC) of less than 2.0, preferably less than 1.7, more preferably less than 1.5, and still more preferably less than 1.0. The tube-form implant 10 preferably has a Radial Expansion Ratio (RER) of less than 30, preferably less than 20, more preferably less than 10, and still more preferably less than 5. The tube-form implant preferably has a ratio of Reduction Ratio (RR) to Lubricant Level (LL) of less than 5. The 15 tube-form implant preferably has the characteristic of maintaining its structural integrity until the tube-form implant is radially expanded by more than 50%, preferably by more than 75%, more preferably by more than 100%, and still more preferably by more than 150%. The tubular 20 implant preferably has the characteristic of substantially retaining its expanded size, structural integrity, and substantial tensile strength when expanded 200% beyond its delivery diameter so that increase in outward radial force is required before further radial 25 expansion can occur.

In some embodiments, the expandable tubular implant is preferably combined with an endovascular stent, e.g., in the form or a cover or a liner, or both, for an endovascular stent. The expandable tubular 30 implant preferably has the characteristic of being expandable by an angioplasty balloon catheter at a pressure of about 5 to 15 atmospheres. The tubular implant preferably has the characteristic that its longitudinal length does not substantially change as a 35 result of radial expansion. The medical implant

- 7 -

preferably has the characteristic of maintaining its structural integrity when expanded by 50%-400%, or more, so that increase in the radial force is required before further expansion can occur.

5 In some preferred embodiments, the tubular medical implant is disposed on the exterior wall surface of the at least one support structure. The tubular medical implant has first and second ends, and, in some preferred embodiments, there are preferably two of the support
10 structures disposed within the interior wall surface of the medical implant at first and second ends thereof, respectively. In some embodiments, the tubular medical implant is preferably disposed within the interior wall surface of the at least one support structure. In some
15 embodiments, an extension of the tubular medical implant wraps around an end of the at least one support structure, from the interior wall surface to the exterior wall surface of the support structure. In some other embodiments, the first tubular medical implant is
20 disposed within the interior wall surface of the at least one support structure and a second tubular implant is disposed about the exterior wall surface of the at least one support structure.

In some preferred embodiments, the at least one
25 radially expandable support structure retains its shape upon expansion to the expanded diameter state as a result of deformation beyond the elastic limit of the material forming the support structure. In some embodiments, the radially expandable support structure is radially self-
30 expandable to the expanded diameter state. In some preferred embodiments the radially expandable support structure is self-expanding as a result of thermal activation. The support structure is preferably formed from stainless steel or nitinol. The tubular medical

- 8 -

implant may preferably be coated with a pharmacological agent.

Embodiments of the invention may include one or more of the following advantages. The invention provides

5 improved PTFE products which are amenable to use as liners and covers for expandable stents. The invention also provides improved tubular PTFE products which substantially retain their structural integrity after the products are radially expanded. The invention enables

10 extension of the length of anatomy which can be treated with an expandable stent.

The following examples are presented to illustrate the presently preferred embodiments of and practice of the invention and not by way of limitation of the scope

15 of the invention; other features and advantages will become apparent from the following description and from the claims.

Brief Description of the Drawings

Fig. 1 is a somewhat diagrammatic view of a

20 preform and an extruded tube.

Figs. 2-2A are diagrammatic side views of an endovascular stent formed with radially expanded pre-dilated polytetrafluoroethylene in a contracted diameter state and an expanded diameter state, respectively.

25 Figs. 3-3A are diagrammatic side views of an endovascular stent formed with radially expanded pre-dilated polytetrafluoroethylene in a contracted diameter state and an expanded diameter state, respectively.

Figs. 4-4A are diagrammatic side views of an

30 endovascular stent formed with radially expanded pre-dilated polytetrafluoroethylene in a contracted diameter state and an expanded diameter state, respectively.

Figs. 5-5A are diagrammatic side views of an endovascular stent formed with radially expanded pre-

- 9 -

dilated polytetrafluoroethylene in a contracted diameter state and an expanded diameter state, respectively.

Figs. 6-6A are diagrammatic side views of an endovascular stent formed with radially expanded pre-
5 dilated polytetrafluoroethylene in a contracted diameter state and an expanded diameter state, respectively.

Figs. 7-7A are diagrammatic side views of an endovascular stent formed with radially expanded pre-
dilated polytetrafluoroethylene in a contracted diameter
10 state and an expanded diameter state, respectively.

Description of the Preferred Embodiments

Examples 1-17, below, concern expandable PTFE material formed as a result of stretching and subsequent sintering, as described in the inventor's co-pending
15 application U.S. Serial No. 08/239,239, filed May 6, 1994. Examples 18-23, below, concern expandable PTFE material formed as a result of expansion in a first dimension, sintering, pre-dilating in a second dimension, and re-sintering.

20 Porous, Highly Crystalline PTFE:

EXAMPLE 1

One hundred grams of FLUON CD123 resin produced by ICI Americas, Inc. was sifted through a No. 10 sieve and then blended at room temperature with twenty-five grams
25 of ISOPAR M solvent produced by Exxon Corporation to produce a preform blend. Other lubricants well known in the art includes VM&P NAPHTHA (boiling point (bp) 118-130°C), ISOPAR (Registered trademark of Exxon Corporation), ISOPAR 3 G (bp 159-174°C), ISOPAR H (bp 30 176-189°C), Low Odor Paraffin Solvent (bp 191-246°C), and SHELLSOL (Trademark of Shell Oil) K.

The resulting preform blend was allowed to sit for over eight hours before being re-sifted through a No. 10 sieve. The lubricant level (LL) equals the weight of
35 solvent used divided by the weight of resin used, which

- 10 -

means the lubricant level utilized in this Example 1 was 25%. In the practice of the invention the lubricant level is normally in the range of 16% to 35%, and is presently preferably in the range of about 18% to 25%.

5 Referring to Fig. 1, a preform charge 10 was created by compacting the preform blend under 200 to 400 psi for approximately one minute in a stainless steel cylinder containing a center shaft. The center shaft extended along the centerline X of and was concentric 10 with the cylinder. The resulting preform charge 10 was a hollow cylindrical mass having a doughnut shaped circular cross sectional area 13, as shown in the drawing. The cylindrical hollow 15 in the preform was occupied by the center shaft. The preform charge was then loaded into a 15 cylindrical barrel in a ram extruder and was extruded into several individual lengths of cylindrical thin-walled tubing 11 at a reduction ratio (RR) of 125:1. The total length of tubing 11 produced from the preform charge was about twenty feet. The extruded tubing had a 20 microstructure characterized by nodes interconnected by fibrils. The reduction ratio equals the ratio of the cross sectional area 13 of the preform to the cross sectional area 14 of the wall of the tubing 11. In the practice of the invention, the RR is less than 200 or 300 25 to 1; preferably equal to or less than 125:1. The ratio of the RR to the LL in the practice of the invention is preferably less than five. In prior art preform blends the ratio of the RR to the LL is normally greater than five, and is typically nine or greater.

30 The solvent was removed from the extruded tubing by placing the tubes in a forced-air circulation electric oven at 255 degrees C for thirty minutes. As used herein, the length of the tube after it is extruded and heated at 255 degrees C to remove the solvent is termed 35 the original length of the tube.

- 11 -

After being heated to 255 degrees C, each tube was heated to 290 degrees C for five minutes and then stretched longitudinally at rate of about 100% per second to a length four times the original length of the tube.

5 Each tube can, if desired, be stretched at a rate in the range of 5% to 500% per second and stretched to a length in the range of two to six times the original length of the tube.

The stretched porous tubes were then sintered at 10 approximately 300 degrees C for forty-five to 90 seconds. The sintering crystallized the PTFE and increased the strength of the porous tubes. During sintering each end of the tubes was restrained to prevent longitudinal shrinkage of the tube. The resulting stretched, 15 sintered, porous tubes consisted essentially of highly crystalline PTFE polymer and had a microstructure characterized by nodes interconnected by fibrils.

The FLUON CD123 resin is a white free-flowing powder made by coagulation of an aqueous dispersion of 20 polytetrafluoroethylene (PTFE). It is designed for paste extrusion with volatile hydrocarbon lubricants for applications in which opacity in the sintered article is not a problem. FLUON CD123 has a relatively high molecular weight. Unsintered extrudates exhibit good 25 green strength.

- 12 -

TYPICAL PROPERTIES OF FLUON CD 123				
	Property	Nominal Value	Units	Test Method
5	Apparent Density	500	grams/liter	ASTM D 1457-83
10	Median Particle Size	500	microns	ASTM D 1457-83
15	Melting Point	327	°C	ASTM D 1457-83
	Color	White		
	Specific Gravity	2.16-2.18		ASTM D 1457-83
	Moisture Content (Max.)	0.04	%	ASTM D 1457-83
	Extrusion Pressure	15000	psi	

EXAMPLE 2

Example 1 was repeated except that twenty grams of
 20 ISOPAR M solvent was utilized instead of twenty-five
 grams and the pre-form charge was extruded at a reduction
 ratio (RR) of 91:1 into cylindrical thin-walled tubing.
 Approximately twenty feet of cylindrical tubing was
 produced.

EXAMPLE 3

Example 1 was repeated except that eighteen grams
 of ISOPAR M solvent was utilized instead of twenty-five
 grams and the pre-form charge was extruded at a reduction
 ratio (RR) of 48:1 into cylindrical thin-walled tubing.
 30 Approximately ten feet of thin-walled tubing was
 produced.

EXAMPLE 4

Example 1 was repeated except that eighteen grams
 of ISOPAR M solvent was utilized instead of twenty-five
 35 grams; ninety-five grams of CD123 was utilized instead of
 one hundred grams; five grams of CD509 was combined with

- 13 -

the ISOPAR M solvent and the CD123; and, the resulting pre-form charges was extruded at a reduction ratio (RR) of 48:1 into cylindrical thin-walled tubing.

Approximately ten feet of thin-walled tubing was

5 produced.

The FLUON CD509 resin is a white, free-flowing powder made by coagulation of an aqueous dispersion of polytetrafluoroethylene (PTFE). It is designed for paste extrusion at medium to high reduction ratios where high 10 sintering rates are desirable.

TYPICAL PROPERTIES OF FLUON CD 123				
	Property	Nominal Value	Units	Test Method
15	Apparent Density	500	grams/liter	ASTM D 1457-83
20	Median Particle Size	500	microns	ASTM D 1457-83
25	Melting Point	327	°C	ASTM D 1457-83
30	Color	White		
	Specific Gravity	2.18-2.20		ASTM D 1457-83
	Moisture Content (Max.)	0.04	%	ASTM D 1457-83
	Extrusion Pressure	8700	psi	

EXAMPLE 5

Three tubes approximately thirty-five centimeters 30 long produced in Example 1 were each tested as follows.

An appropriate size angioplasty balloon catheter manufactured by Boston Scientific was placed in the inner lumen of the tube and was inflated with water with a standard MONARCH endoflator at a rate of approximately 35 ten psi per second. Merit Medical manufacture the

- 14 -

MONARCH endoflater. The balloon was about four centimeters long. As is well known, the balloon catheter is normally inserted in a blood vessel by first inserting a wire in a vessel; then inserting a vessel dilator along 5 the wire into the vessel; removing the vessel dilator; inserting an introducer sleeve along the wire into the vessel; inserting the balloon; removing the introducer sleeve; inflating the balloon; deflating the balloon; removing the balloon; and removing the wire. A similar 10 procedure was used while utilizing the balloon catheter to test the PTFE tubes of Example 1.

The balloon catheter did not apply an outward expansion force against the tube until the catheter was inflated under pressure with water. Inflation of the 15 balloon (and the concomitant increase in inflation pressure) was stopped at predetermined pressure intervals of one or one-half atmosphere pressure to measure the outside diameter of each tube. Each tube was dilated until it burst.

20 The actual inflation pressure was observed on a digital pressure gauge and recorded. The percent dilatation was calculated by measuring the tubing outside diameter with digital calipers at each pressure interval and then using the following formula:

25
$$\% \text{ Dilatation} = [(D_d - D_i) / (D_i)] \times 100$$

where D_i = initial tube diameter at pressure equal to zero

D_d = measured dilated tubing diameter

From the raw data, REC (Radial Expansion Coefficient), 30 REL (Radial Expansion Limit), and RER (Radial Expansion Ratio) were calculated and recorded along with the calculated reduction ratio to lubricant level ratio (RR/LL), where:

P_{\max} = Maximum Inflation Pressure

35 P_{burst} = Burst Inflation Pressure

- 15 -

%RD = Percent Radial Dilatation

REC = $(P_{max}) / (\% RD \text{ at } P_{max})$

REL = $(P_{burst}) / (\% RD \text{ at } P_{burst})$

RER = $(REC) / (REL)$

5 As used herein, a tube retains its structural integrity after being radially expanded as long as the tube requires the application of an increased inflation pressure before the amount of radial expansion of the tube increases. If a tube continues to expand when the 10 amount of inflation pressure decreases, then the tube has lost its structural integrity. When the P_{max} of a tube is exceeded, the tube loses its structural integrity. However, the loss in structural integrity results in degradations of physical properties which are 15 significantly less than those which occur in prior art PTFE tubes. For example, at a percent dilatation of about 300% in Table I below, the tube still retains about 70% to 75% of its pre-dilatation tensile strength. Also, in Table I below, Tube No. 1 loses its structural 20 integrity at an inflation pressure greater than 6.5 atm (P_{max}). In Tables II and III below, Tubes No. 2 and 3, respectively also lose their structural integrity at an inflation pressure greater than 6.5 atm (P_{max}).

The following results were obtained for the three 25 Example 1 tubes which were tested:

- 16 -

Tube No. 1

Table I: Tube No. 1 Measurements

<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilatation</u>
1	0	2.75	-
5	1	2.75	0
6	2	2.75	0
10	3	3.05	11
7	3.5	3.13	14
8	4	3.20	16
9	4.5	3.34	21
10	5	3.37	23
11	5.5	3.92	43
15	6	4.62	68
11	6.5 (P _{max})	5.34	94
12	4.5 (P _{burst})	12.12	341

$$REC = (6.5 \text{ atm} \times 14.7 \text{ psi/atm})/94\% = 1.02 \text{ psi}/\%$$

$$REL = (4.5 \text{ atm} \times 14.7 \text{ psi/atm})/341\% = 0.19 \text{ psi}/\%$$

$$RER = (1.02)/(0.19) = 5.4$$

- 17 -

Tube No. 2

Table II: Tube No. 2 Measurements

	<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilatation</u>
5	1	0	2.67	-
	2	1	2.67	0
	3	2	2.87	7
	4	3	3.02	13
	5	3.5	3.02	13
	6	4	3.17	19
	7	4.5	3.23	21
	8	5	3.40	27
	9	5.5	3.64	36
	10	6	4.77	79
	11	6.5 (P_{max})	5.51	106
15	12	4.5 (P_{burst})	12.51	369

$$REC = (6.5 \text{ atm} \times 14.7 \text{ psi/atm})/106\% = 0.90 \text{ psi}/\%$$

$$REL = (4.5 \text{ atm} \times 14.7 \text{ psi/atm})/369\% = 0.18 \text{ psi}/\%$$

$$RER = (0.90)/(0.18) = 5.0$$

- 18 -

Tube No. 3

Table III: Tube No. 3 Measurements

<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilatation</u>
1	0	2.75	-
5	2	2.75	0
6	3	3.05	11
10	3.5	3.13	14
7	4	3.20	16
8	4.5	3.34	21
9	5	3.37	23
10	5.5	3.92	43
11	6	4.62	68
15	6.5 (P_{max})	5.34	94
12	4.5 (P_{burst})	12.97	372

$$REC = (6.5 \text{ atm} \times 14.7 \text{ psi/atm})/94\% = 0.90 \text{ psi}/\%$$

$$REL = (4.5 \text{ atm} \times 14.7 \text{ psi/atm})/372\% = 0.18 \text{ psi}/\%$$

$$RER = (0.90)/(0.18) = 5.7$$

EXAMPLE 6

20 Three tubes approximately thirty-five centimeters long produced in Example 2 were each tested utilizing the equipment and procedure described in EXAMPLE 5. The following results were obtained for the three Example 2 tubes tested.

- 19 -

Tube No. 1

5

Table IV: Tube No. 1 Measurements			
<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilatation</u>
1	0	4.27	-
2	1	4.27	0
3	2	4.27	0
4	3	4.35	2
5	3.5	5.85	37
6	4 (P_{max})	9.08	113
10	2.5 (P_{burst})	16.39	284

$$REC = (4.0 \text{ atm} \times 14.7 \text{ psi/atm})/113\% = 0.52 \text{ psi}/\%$$

$$REL = (2.5 \text{ atm} \times 14.7 \text{ psi/atm})/284\% = 0.13 \text{ psi}/\%$$

$$RER = (0.52)/(0.13) = 4.0$$

Tube No. 2

15

Table V: Tube No. 2 Measurements			
<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilatation</u>
1	0	4.74	-
2	1	4.74	0
3	2	4.74	0
20	3	5.49	16
5	3.5	7.09	50
6	4 (P_{max})	10.00	111
7	3 (P_{burst})	20.52	333

$$REC = (4 \text{ atm} \times 14.7 \text{ psi/atm})/111\% = 0.53 \text{ psi}/\%$$

$$25 \text{ REL} = (3 \text{ atm} \times 14.7 \text{ psi/atm})/333\% = 0.13 \text{ psi}/\%$$

$$RER = (0.53)/(0.13) = 4.1$$

- 20 -

Tube No. 3

Table VI: Tube No. 3 Measurements				
	<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilatation</u>
5	1	0	4.83	-
	2	1	4.83	0
	3	2	4.83	0
	4	3	5.23	8
	5	3.5	6.00	24
	6	4 (P_{max})	9.66	100
	7	3 (P_{burst})	18.12	275

$$REC = (4 \text{ atm} \times 14.7 \text{ psi/atm})/100\% = 0.59 \text{ psi}/\%$$

$$REL = (3 \text{ atm} \times 14.7 \text{ psi/atm})/275\% = 0.16 \text{ psi}/\%$$

$$RER = (0.59)/(0.16) = 3.7$$

EXAMPLE 7

15 Two tubes approximately thirty-five centimeters long produced in Example 3 were each tested utilizing the

- 21 -

equipment and procedure described in EXAMPLE 5. The following results were obtained for the two tubes tested.

Tube No. 1

Table VII: Tube No. 1 Measurements			
Measurement	Inflation Pressure (Atm)	Diameter (mm)	% Dilation
1	0	6.04	-
2	1	6.28	4
3	1.5	6.45	7
4	2	6.79	12
5	2.5	7.15	18
6	3	7.39	22
7	3.5	8.33	38
8	4 (P _{max})	9.82	63
9	3.7 (P _{burst})	24.77	310

$$15 \text{ REC} = (4.0 \text{ atm} \times 14.7 \text{ psi/atm})/63\% = 0.93 \text{ psi/}\%$$

$$\text{REL} = (3.7 \text{ atm} \times 14.7 \text{ psi/atm})/310\% = 0.18 \text{ psi/}\%$$

$$\text{RER} = (0.93)/0.18) = 5.2$$

- 22 -

Tube No. 2

Table VIII: Tube No. 2 Measurements				
	<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilation</u>
5	1	0	5.99	-
	2	1	6.65	11
	3	1.5	6.76	13
	4	2	7.01	17
	5	2.5	7.31	22
	6	3	7.73	29
10	7	3.5	8.43	41
	8	4	9.09	52
	9	4.5 (P_{max})	11.17	89
	10	3.9 (P_{burst})	25.62	328

$$REC = (4.5 \text{ atm} \times 14.7 \text{ psi/atm})/86\% = 0.77 \text{ psi/}%$$

$$15 \text{ REL} = (3.9 \text{ atm} \times 14.7 \text{ psi/atm})/328\% = 0.17 \text{ psi/}%$$

$$\text{RER} = (0.77)/0.17) = 4.5$$

EXAMPLE 8

Two tubes approximately thirty-five centimeters long produced in Example 4 were each tested utilizing the 20 equipment and procedure described in EXAMPLE 5. The following results were obtained for the two tubes tested.

- 23 -

Tube No. 1

Table IX: Tube No. 1 Measurements				
	<u>Measurement</u>	Inflation Pressure (Atm)	Diameter (mm)	% Dilation
5	1	0	5.94	-
	2	1	6.40	8
	3	1.5	6.55	10
	4	2	7.02	18
	5	2.5	7.58	28
10	6	3	9.51	60
	7	3.5 (P_{max})	13.15	121
	8	2.9 (P_{burst})	24.15	307

$$REC = (3.5 \text{ atm} \times 14.7 \text{ psi/atm})/121\% = 0.43 \text{ psi}/\%$$

$$REL = (3.9 \text{ atm} \times 14.7 \text{ psi/atm})/328\% = 0.14 \text{ psi}/\%$$

$$RER = (0.43)/.014) = 3.1$$

- 24 -

Tube No. 2

Table X: Tube No. 2 Measurements				
	<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilation</u>
5	1	0	5.90	-
	2	1	6.41	9
	3	1.5	6.89	17
	4	2	7.09	20
	5	2.5	7.83	33
	6	3	8.34	41
10	7	3.5	9.90	68
	8	4 (P_{max})	13.05	121
	9	3.1 (P_{burst})	24.76	320

$$REC = (4.0 \text{ atm} \times 14.7 \text{ psi/atm})/121\% = 0.49 \text{ psi/}%$$

$$REL = (3.1 \text{ atm} \times 14.7 \text{ psi/atm})/320\% - 0.14 \text{ psi/}%$$

$$15 \text{ RER} = (0.49)/0.14 = 3.5$$

EXAMPLE 9

Example 5 is repeated, except that after measurements are made at each pressure interval which causes the tube to dilate, the pressure is reduced by 20 about one atmosphere to give the tube an opportunity to contract and five minutes later the diameter of the tube is remeasured. For example, after measurement no. 4 in Table I, the pressure is reduced to two atmospheres and five minutes later the diameter of the tube is remeasured. Each time the diameter of the tube is remeasured, the diameter of the tube is reduced by about 10% or less from the 25 measurement made when the pressure was one atmosphere. After example 5 in Table I, the pressure is reduced to two and a half atmospheres and five minutes later the diameter of the tube is remeasured; etc. Each time the diameter of the tube is remeasured, the diameter of the tube is reduced by about 10% or less from the 30 measurement made when the pressure was one atmosphere.

- 25 -

greater. For example, after measurement no. 4 (3.05 mm) is taken in Table I, the water pressure is reduced to two atmospheres, and the diameter of the tube is measured five minutes later, the diameter of the tube is 2.75 mm.

5

EXAMPLE 10

Example 1 is repeated except that the stretch rate is 10% per second instead of 100% per second.

EXAMPLE 11

Example 1 is repeated except that the stretch rate 10 is 300% per second instead of 100% per second.

EXAMPLE 12

Example 1 is repeated except that the tube is stretched to three times its original length instead of four times its original length.

15

EXAMPLE 13

Example 1 is repeated except that the tube is stretched to six times its original length instead of four times its original length.

EXAMPLE 14

20 Example 5 is repeated utilizing tubes produced during Example 10. Similar results are obtained.

EXAMPLE 15

Example 5 is repeated utilizing tubes produced during Example 11. Similar results are obtained.

25

EXAMPLE 16

Example 5 is repeated utilizing tubes produced during Example 12. Similar results are obtained.

EXAMPLE 17

30 Example 5 is repeated utilizing tubes produced during Example 13. Similar results are obtained.

Radially Pre-Dilated PTFE:

As described in the above examples, a porous hollow tube (or sheet or other shape) which consists

essentially of highly crystalline polytetrafluoroethylene polymer and which has a microstructure characterized by nodes interconnected by fibrils is formed by extruding a lubricant/polytetra-fluoroethylene resin composition into 5 a hollow tube, by heating the tube to remove the lubricant, by stretching the tube, and, while holding the tube in its stretched configuration, by sintering the tube at or above the melting temperature of the polytetrafluoroethylene resin to form a porous highly 10 crystalline polytetrafluoroethylene polymer tube. This sintered porous tube of highly crystalline PTFE polymer has original inner and outer diameters.

As used herein, the terminology "radially pre-dilated" means that a porous highly crystalline 15 polytetrafluoroethylene polymer tube is first radially dilated to increase the original inner (and outer) diameter of the tube and is then sintered to cause the dilated tube to contract radially to a configuration in which the diameter of the tube is less than the radially 20 dilated diameter. When the radially dilated tube is sintered, the dilated tube is presently preferably contracted to a configuration in which the diameter of the tube substantially equals its original inner diameter. For example, and not by way of limitation, a 25 sintered porous (the word "porous" indicates the extruded tube has been stretched along its longitudinal axis subsequent to being heated to remove lubricant and prior to being sintered to form highly crystalline PTFE polymer) tube of highly crystalline PTFE polymer having 30 an inner diameter of three mm is radially pre-dilated by radially dilating the tube to an inner diameter (ID) of fifteen millimeters and by then sintering the tube to cause the tube to radially contract to an inner diameter of six mm. Similarly, the three mm ID sintered porous 35 tube of highly crystalline PTFE polymer is radially pre-

- 27 -

dilated by radially dilating the tube to an ID of six millimeters and by then sintering the tube to cause the tube to radially contract to an inner diameter to equal to its original inside diameter of three mm.

5

EXAMPLE 18

One hundred grams of FLUON CD 123 resin produced by ICI Americas, Inc, was sifted through a No. 10 sieve and then blended at room temperature with twenty-five grams of ISOPAR M solvent (lubricant level 25%) produced 10 by Exxon Corporation to produce a preform blend.

The resulting preform blend was allowed to sit for over eight hours before being re-sifted through a No. 10 sieve.

Referring again to Fig. 1, a preform charge 10 was 15 created by compacting the preform blend under 200 to 400 psi for approximately one minute in a stainless steel cylinder containing a center shaft. The center shaft extended along the centerline X of and was concentric with the cylinder. The resulting preform charge 10 was a 20 hollow cylindrical mass having a doughnut-shaped circular cross sectional area 13, as shown in Fig. 1. The cylindrical hollow 15 in the preform was occupied by the center shaft. The preform charge was then loaded into a cylindrical barrel in a ran extruder and was extruded 25 into several individual lengths of cylindrical thin-walled tubing 11 at a reduction ratio (RR) of 48:1. The total length of tubing 11 produced from the preform charge was about twenty feet. The extruded tubing had an inner diameter of five mm and had a microstructure 30 characterized by nodes interconnected by fibrils.

The solvent was removed from the extruded tubing by placing the tubes in a forced-air circulation electric oven at 255 degrees C for thirty minutes. As used herein, the length of the tube after it is extruded and

- 28 -

heated at 255 degrees C to remove the solvent is termed the original length of the tube.

A tube nine centimeters long was selected. After being heated to 255 degrees C, each tube was heated to 5 290 degrees C for five minutes and was then stretched longitudinally for the first time at rate of about 100% per second to a length four time the original length of the tube, i.e., to a tube thirty-six cm long.

The stretched porous thirty-six cm long tube was 10 then sintered at approximately 360 degrees C for forty-five to ninety seconds. The sintering crystallized the PTFE and increased the strength of the porous tubes. During sintering each end of the tube was restrained to prevent longitudinal shrinkage of the tube. The 15 resulting stretched, sintered, porous tubes consisted essentially of highly crystalline PTFE polymer and had a microstructure characterized by nodes interconnected by fibrils.

The sintered thirty-six cm long tube was pre-20 dilated by radially dilating the tube along its entire length to a twenty-four mm inner diameter. The tube was dilated by using an angioplasty balloon catheter in the manner described in Example 3, above.

The dilated tube was re-sintered at 355 degrees C 25 for four minutes to cause the tube to contract radially and return to its original diameter of five mm and original length of nine cm. The tube was not restrained during sintering. Sintering the dilated tube at 355 degrees C completed the pre-dilation procedure.

30 The pre-dilated five mm diameter and nine cm long tube was heated to 300 degrees C for five minutes and stretched a second time to a length of eighteen centimeters.

- 29 -

EXAMPLE 19

The eighteen centimeter long tube produced in Example 18 was tested using the angioplasty balloon catheter and procedure described in Example 5. The 5 results obtained are shown below in Table XI.

Table XI: Measurements for Example 18 Tube				
	Measurement	Inflation Pressure (Atm)	Diameter (mm)	% Dilation
	1	0	6.01	-
	2	1	6.01	0
10	3	2	6.19	3
	4	3	6.80	13
	5	4.0	6.90	15
	6	5.0	7.01	17
	7	6.0	7.68	28
15	8	7.0	8.40	40
	9	*7.5	23.67	294

*P_{max} and P_{burst}

$$\text{REC} = (7.5 \text{ atm} \times 14.7 \text{ psi/atm})/294\% = 0.375 \text{ psi/\%}$$

$$20 \text{ REL} = (7.5 \text{ atm} \times 14.7 \text{ psi/atm})/294\% = 0.375 \text{ psi/\%}$$

$$\text{RER} = (0.375)/(0.375) = 1.0$$

From an endovascular grafting perspective, an RER of 1.0 is an ideal value because the maximum pressure is 25 equal to the burst pressure. This permits the ready dilation of a polytetrafluoroethylene tube without exceeding the maximum pressure. Exceeding the maximum pressure results in the loss of structural integrity.

As would be appreciated by those of skill in the 30 art, the amount by which an extruded tube is lengthened before it is sintered to produce highly crystalline

- 30 -

polytetrafluoroethylene polymer can be varied as desired to control the amount of pressure required to dilate a tube. The more a tube is lengthened, the less dense the wall of the tube and the less pressure required to dilate 5 the tube. Similarly, the amount by which the tube is pre-dilated can be varied as desired. In Example 18, the tube was pre-dilated to a diameter equal to about five times the original diameter and was lengthened the second time to a length (equal to twice the original extruded 10 length) which was only one-half of the length (equal to four times the original extruded length) at which the tube was pre-dilated to 24 mm. As a result, the maximum inflation pressure occurred when the tube was radially dilated to an outer diameter of about 23.67 mm. The 15 amount by which the tube is lengthened the second time and the amount of pre-dilated can be varied to alter the amount of tube dilation required to reach the maximum inflation pressure, P_{max} .

EXAMPLE 20

20 Example 18 was repeated, except that after the pre-dilated tube was five mm inner diameter and nine cm long tube was heated to 300 degrees C for five minutes and stretched a second time, the tube was stretched to a length of thirteen and a half centimeters instead of a 25 length of eighteen centimeters.

EXAMPLE 21

The thirteen and a half centimeters long tube produced in Example 20 was tested using an angioplasty balloon catheter and procedure described in Example 5. 30 The results obtained are shown below in Table XII. The tubes are generally expandable by an angioplasty balloon catheter inflated to pressures of at least about 5 to 15 atmospheres.

- 31 -

Table XII: Measurements for Example

Measurement	Inflation Pressure (Atm)	Diameter (in)	Tube	% Dilation
1	0	6.48		-
2	3	6.48		0
3	4	6.71		4
4	5	6.71		4
5	6	6.87		6
6	7	6.87		6
7	8	6.87		6
8	9	7.17		11
9	10	7.83		21
10	11	8.68		34
11	12	11.92		84
12	*12.5	24.28		275

15 *P_{max} and P_{burst}

$$REC = (12.5 \text{ atm} \times 14.7 \text{ psi/atm})/275\% = 0.69 \text{ psi/}%$$

$$REL = (12.5 \text{ atm} \times 14.7 \text{ psi/atm})/275\% = 0.69 \text{ psi/}%$$

$$RER = (0.69)/(0.69) = 1.0$$

The results in Table XII demonstrate that increasing the density of the wall of the tube increased the pressure needed to dilate the tube. As the density of the wall of the tube is increased the amount by which the tube is stretched. The percent dilatation at P_{max} can be adjusted to desired values by varying the amount by which the tube is pre-dilated and the amount by which the tube is stretched. The values of P_{max} and percent dilation at P_{max} are limited by the physical properties of the polytetrafluoroethylene utilized to prepare the tube.

also
ng. The
reducing
P_{max} and
asonable
e tube is
ation at
ne
tubing.

- 32 -

EXAMPLE 22

One hundred grams of FLUON CD123 resin produced by ICI Americas, Inc. was sifted through a No. 10 sieve and then blended at room temperature with eighteen grams of 5 ISOPAR M solvent (18% lubricant level) produced by Exxon Corporation to produce a preform blend.

The resulting preform blend was allowed to sit for over eight hours before being re-sifted through a No. 10 sieve. A preform charge 10 was created by compacting the 10 preform blend under 200 to 400 psi for approximately one minute in a stainless steel cylinder containing a center shaft. The center shaft extended along the centerline X of and was concentric with the cylinder. The resulting preform charge 10 (Fig. 1) was a hollow cylindrical mass 15 having a doughnut-shaped circular cross sectional area 13, as shown in Fig. 1. The cylindrical hollow 15 in the preform was occupied by the center shaft. The preform charge was then loaded into a cylindrical barrel in a ram extruder and was extruded into several individual lengths 20 of cylindrical thin-walled tubing 11 at a reduction ratio (RR) of 51:1. The total length of tubing 11 produced from the preform charge was about twenty feet. The extruded tubing had an inner diameter of three mm and had a microstructure characterized by nodes interconnected by 25 fibrils.

The solvent was removed from the extruded tubing by placing the tubes in a force-air circulation electric oven at 255 degrees C for thirty minutes. As used herein, the length of the tube after it is extruded and 30 heated at 255 degrees C to remove the solvent is termed the original length of the tube.

First and second tubes each nine centimeters long were selected. After being heated to 255 degrees C, each tube was heated to 290 degrees C for five minutes and was 35 then stretched longitudinally for the first time at rate

- 33 -

of about 100% per second to a length three times the original length of the tube, i.e., to a tube twenty-seven cm long.

The pair of stretched porous twenty-seven cm long tubes were then sintered at approximately 360 degrees C for forty-five to ninety seconds. The sintering crystallized the PTFE and increased the strength of the porous tubes. During sintering each end of the tube was restrained to prevent longitudinal shrinkage of the tube.

10 The resulting stretched, sintered, porous tubes consisted essentially of highly crystalline PTFE polymer and had a microstructure characterized by nodes interconnected by fibrils.

The first sintered twenty-seven cm long tube was 15 tested using the angioplasty balloon catheter and procedure described in Example 5. The results obtained are shown below in Table XIII.

Table XIII: Measurements for First Example 22 Tube

<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilation</u>
1	0	5.34	-
2	1	5.43	2
3	2	5.43	2
4	3	5.43	2
5	4	5.43	2
20 6	5	5.58	4
7	6 (P_{max})	6.55	23
25 8	5 (P_{burst})	20.76	291

REC = 3.83 psi/%

REL = 0.25 psi/%

30 RER = 15.3

- 34 -

The second sintered twenty-seven cm long tube was pre-dilated by radially dilating the tube along its entire length to a ten mm inner diameter. The tube was dilated by using an angioplasty balloon catheter in the 5 manner described in Example 3.

The dilated tube was re-sintered at 355 degrees C for four minutes to cause the tube to radially contract and return to its original diameter of three mm and original length of nine cm. Sintering the dilated tube 10 at 355 degrees C completed the pre-dilating procedure.

The pre-dilated five mm diameter and nine cm long tube was heated to 300 degrees C for five minutes and stretched a second time to a length of eighteen centimeters. The eighteen centimeter pre-dilated tube 15 produced in this Example 22 was then tested using the angioplasty balloon catheter and procedure described in Example 5. The results obtained are shown below in Table XIV.

20 Table XIV: Measurements for Second Example 22 Tube
(Pre-Dilated)

Measurement	Inflation Pressure (Atm)	Diameter (mm)	% Dilation
1	0	5.38	-
2	1	5.38	0
3	2	5.38	0
4	3	5.38	0
5	4	5.38	0
6	5	5.38	0
7	6 (P _{max})	6.56	22
8	5.5 (P _{burst})	19.26	258

30 REC = 4.01 psi/%

REL = 0.31 psi/%

RER = 12.9

- 35 -

EXAMPLE 23

One hundred grams of FLUON CD123 resin produced by ICI Americas, Inc. was sifted through a No. 10 sieve and then blended at room temperature with eighteen grams of 5 ISOPAR M solvent (18% lubricant level) produced by Exxon Corporation to produce a preform blend.

The resulting preform blend was allowed to sit for over eight hours before being re-sifted through a No. 10 sieve. A preform charge 10 (Fig. 1) was created by 10 compacting the preform blend under 200 to 400 psi for approximately one minute in a stainless steel cylinder containing a center shaft. The center shaft extended along the centerline X of and was concentric with the cylinder. The resulting preform charge 10 was a hollow 15 cylindrical mass having a doughnut-shaped circular cross sectional area 13, as shown in Fig. 1. The cylindrical hollow 15 in the preform was occupied by the center shaft. The preform charge was then loaded into a cylindrical barrel in a ram extruder and was extruded 20 into several individual lengths of cylindrical thin-walled tubing 11 at a reduction ratio (RR) of 51:1. The total length of tubing 11 produced from the preform charge was about twenty feet. The extruded tubing had an inner diameter of three mm and had a microstructure 25 characterized by nodes interconnected by fibrils.

The solvent was removed from the extruded tubing by placing the tubes in a forced-air circulation electric oven at 255 degrees C for thirty minutes. As used herein, the length of the tube after it is extruded and 30 heated at 255 degrees C to remove the solvent is termed the original length of the tube.

First, second, and third tubes each nine centimeters long were selected. After being heated to 255 degrees C, each tube was heated to 290 degrees C for 35 five minutes and was then stretched longitudinally for

- 36 -

the first time at a rate of about 100% per second to a length seven times the original length of the tube, i.e., to a tube sixty-three cm long.

The trio of stretched porous sixty-three cm long tubes were then sintered at approximately 360 degrees C for forty-five to ninety seconds. The sintering crystallized the PTFE and increased the strength of the porous tubes. During sintering each end of the tube was restrained to prevent longitudinal shrinkage of the tube. The resulting stretched, sintered, porous tubes consisted essentially of highly crystalline PTFE polymer and had a microstructure characterized by nodes interconnected by fibrils.

The first sintered sixty-three cm long tube was tested using the angioplasty balloon catheter and procedure described in Example 5. The angioplasty balloon was about four cm long. The results obtained are shown below in Table XV.

Table XV: Measurements for First Example 23 Tube
(Tube Not Pre-Dilated)

<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilation</u>
1	0	5.66	-
2	1	5.66	0
3	2	5.66	0
4	3 (P _{max})	5.76	19
5	2.8 (P _{burst})	19.92	252

REC = 2.32 psi/%

REL = 0.16 psi/%

RER = 14.5

The second sintered sixty-three cm long tube was pre-dilated by radially dilating the tube along its entire length to a ten mm inner diameter. The tube was

- 37 -

dilated by using an angioplasty balloon catheter in the manner described in Example 3.

The dilated second tube was restrained longitudinally (so the tube could not contract to a shorter length) and was re-sintered at 350 degrees C for thirty seconds to cause the second tube to return to its original diameter of three mm. After sintering at 350 degrees C, the length of the second tube was the same, i.e., sixty-three cm. Sintering the dilated second tube at 350 degrees C for thirty seconds completed the pre-dilation procedure for the second tube.

The pre-dilated three mm diameter and sixty-three cm long second tube was tested using the angioplasty balloon catheter and procedure described in Example 5. The angioplasty balloon was four cm long. The results obtained are shown below in Table XVI.

Table XVI: Measurements for Second Example 23 Tube (Pre-Dilated; Sintered Under Longitudinal Restraint)				
	<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilation</u>
20	1	0	5.37	-
	2	1	5.72	7
	3	2	5.82	8
	4	3 (P _{max})	7.78	45
	5	2.8 (P _{burst})	20.78	287

25 REC = 0.98 psi/%

REL = 0.14 psi/%

RER = 7.0

The third sintered sixty-three cm long tube was pre-dilated by radially dilating the tube along its entire length to a fifteen mm inner diameter. The tube was dilated by using an angioplasty balloon catheter in the manner described in Example 3.

- 38 -

The dilated third tube was restrained longitudinally (so the tube could not contract to a shorter length) and was re-sintered at 350 degrees C for thirty seconds to cause the tube to return to its original diameter of three mm. The length of the third tube remained the same, i.e., sixty-three cm. Sintering the dilated third tube at 350 degrees C for thirty seconds completed the pre-dilation procedure for the third tube.

The pre-dilated three mm diameter and sixty-three cm long third tube was tested using the angioplasty balloon catheter and procedure described in Example 5. The angioplasty balloon was four cm long. The results obtained are shown below in Table XVII.

15

Table XIII: Measurements for Third Example 23 Tube (Pre-Dilated; Sintered Under Longitudinal Restraint)

20

<u>Measurement</u>	<u>Inflation Pressure (Atm)</u>	<u>Diameter (mm)</u>	<u>% Dilation</u>
1	0	6.00	-
2	1	6.00	0
3	2	7.68	28
4	*2.5	21.14	252

*P_{max} and P_{burst}

25

REC = 0.15 psi/%

REL = 0.15 psi/%

RER = 1.0

As evidenced by Example 23, the PTFE tubing had to be significantly pre-dilated, i.e., up to a diameter equal to five times the original diameter, in order to obtain an RER of 1. The amount of pre-dilation necessary to obtain an RER of 1 can be determined for each particular lubricant/PTFE resin composition and for each selected longitudinal expansion (stretching) of an

- 39 -

extruded tube which is used prior to sintering of an extruded tube to produce a high crystalline PTFE structure. A tube having an RER of 1 will not rupture because when the tube is expanded to a diameter less than 5 the diameter to which the tube is expanded during pre-dilation, the tube retains its structural integrity.

As would be appreciated by those of skill in the art, after a PTFE tube (or sheet or other shaped PTFE article) is (a) lengthened to a first length by being 10 stretched along its longitudinal axis prior to being initially sintered to form a highly crystalline PTFE polymer, and (b) pre-dilated, the tube can again be lengthened by being stretched a second time along its longitudinal axis to a second length less than, equal to, 15 or greater than the first length.

Expandable Endovascular Stents:

Referring to Figs. 2-7A, radially expandable PTFE tubes formed in accordance with the above examples are amenable for use with an endovascular stent as a liner or 20 a cover, or both. Figs. 2-7A are merely intended to be diagrammatic and not limiting; in practical embodiments, there would be a lumen defined through the stents shown in Figs. 2, 3, 4, 5, 6, and 7 for receiving, e.g., a guidewire or a balloon of an angioplasty catheter, which 25 would be used to deliver the stent to the implantation site. Such stents may be used to expand a partially occluded segment of a blood vessel, or other body passageway; it may also be used for other purposes, such as: a supportive graft placed within blocked arteries 30 opened by recanalization; a support within opened vessels which were occluded by inoperative cancers; a support within veins treated for portal hypertension; a supportive graft for the esophagus, intestine, ureters, urethra, and the bile duct; and as a graft for sealing, 35 e.g., an arterio-venous fistula. Such stents are

- 40 -

characterized by a contracted diameter state, which is suitable for delivery through the vasculature of a patient to a desired site, and an expanded diameter state, which is suitable for support of a blood vessel at 5 the desired site. The length and expanded diameter of such stents will depend on the anatomy of the desired implantation site. In some preferred embodiments, such stents have a length of about 0.5-45 cm, a contracted diameter of about 1-6 mm, and an expanded diameter of 10 about 2.5-30 mm. The endovascular stents are preferably delivered to the desired implantation site through an introducer sheath having an outer diameter of about 5-20 Fr.

As shown in Figs. 2 and 2A, a stent 48 includes a 15 radially pre-dilated PTFE tube 50 disposed as a cover about an endovascular stent support structure 52. Stent 48 is useful for treating relatively short vessel lengths, e.g., 0.5-4 cm. The support structure may have different structures.

20 In one embodiment, the support structure is balloon-expandable from a small diameter state to an expanded final diameter state as a result of expansion beyond the elastic limit of the material forming the structure. Accordingly, such a structure should be 25 formed of material which has sufficient strength and elasticity to be expanded and to retain its expanded diameter, e.g., silver, tantalum, stainless steel, gold, titanium, and plastic. Such a structure may be formed of a plurality of intersecting elongate members, which are 30 fixedly secured to one another by welding, soldering, or gluing.

In another embodiment, the support structure is self-expanding. Such a support structure has a natural state of a preselected large diameter, which is 35 compressed into a small diameter state and inserted into

- 41 -

radially pre-dilated tube 50 to form the endovascular stent. The support structure is formed from shape-memory material, e.g., nitinol (nickel titanium alloy), which tends to expand to its original preselected diameter.

5 In yet another embodiment, the support structure is formed from thermally-activated shape memory alloy (e.g., nitinol), which expands to a preselected implantation diameter state at temperatures above a threshold temperature (selected to be below normal body 10 temperature) and is pliable and non-expanding at lower temperatures.

Referring to Figs. 3 and 3A, a stent 54 includes an elongated radially pre-dilated PTFE tube 51 disposed about two support structures 56, 58 located at opposite 15 ends of the tube. For vascular applications, the PTFE tube is generally 5-45 cm long and the support structures are about 1-2 cm long. Stent 54 is useful for supporting or sealing relatively long lengths of body passages. The support structures may be formed in accordance with the 20 structures described above in connection with Figs. 2 and 2A.

As shown in Figs. 4 and 4A, a stent 60 may include more than two support structures disposed inside a radially pre-dilated PTFE tube. In the embodiment shown, 25 there are three such support structures. Stent 60 is useful in areas of the vascular anatomy where there are bends or other anatomical features and in which an additional support prevents collapse of the lumen defined through the stent. The support structures may be formed 30 in accordance with the structures described above in connection with Figs. 2 and 2A.

Referring to Figs. 5 and 5A, a stent 62 includes a tubular liner 64 formed from radially pre-dilated PTFE disposed inside a support structure 66. A plurality of 35 sutures or metal clips 68 fix the PTFE liner 64 to the

- 42 -

radially expandable support structure 66. There is preferably a set of four clips disposed around the circumference the stent, at a plurality of spaced-apart locations along the length of the stent. The support 5 structure may be formed in accordance with the structures described above in connection with Figs. 2 and 2A.

In the embodiment shown in Figs. 6 and 6A, the ends 70, 72 of a tubular liner 74 extend beyond and wrap back over the exterior of ends 76, 78 of a support 10 structure 80. Sutures 82-88 secure the ends of the tubular liner to the support structure. The support structure may be formed in accordance with the structures described above in connection with Figs. 2 and 2A. In an alternative embodiment, support structure 80 is replaced 15 by a plurality of spaced-apart support structures, with two support structures disposed at the ends thereof.

Referring to Figs. 7 and 7A, in another embodiment, a stent 90 includes a support structure 92, formed in accordance with one of the embodiments 20 described in connection with Figs. 2 and 2A, surrounded by a liner 94 and a cover 96, each formed from radially pre-dilated PTFE tubes. Liner 94 is attached to the support structure by a plurality of sutures or clips 98. The support structure may be formed in accordance with 25 the structures described above in connection with Figs. 2 and 2A. In an alternative embodiment, support structure 92 is replaced by a plurality of spaced-apart support structures, with two support structures disposed at the ends thereof.

30 Other embodiments are within the scope of the claims. For example, the radially expanded pre-dilated PTFE tubular implants may be coated with a pharmacological agent, such as heparin or antitumor agents.

- 43 -

Still other embodiments are within the scope of
the claims.

- 44 -

What is claimed is:

1. A method for producing a porous tube comprising essentially of highly crystalline polytetrafluoroethylene polymer, comprising the steps of:
 - (a) extruding a lubricant/polytetrafluoroethylene resin blend to form a tubing having a longitudinal axis, a primary inner diameter, and a primary length;
 - (b) heating the tubing to remove the lubricant;
 - (c) stretching the tubing along the longitudinal axis to produce an elongated tubing having a secondary length greater than the primary length;
 - (d) sintering the elongated tubing to produce a sintered tubing;
 - (e) radially expanding the sintered tubing to produce radially expanded tubing having an expanded inner diameter greater than the primary inner diameter; and
 - (f) sintering the radially expanded tubing to correct the radially expanded tubing.
2. A method for producing a porous tube comprising essentially of highly crystalline polytetrafluoroethylene polymer, comprising the steps of:
 - (a) extruding a lubricant/polytetrafluoroethylene resin blend to form a tubing having a longitudinal axis, a primary inner diameter, and a primary length;
 - (b) heating the tubing to remove the lubricant;
 - (c) stretching the tubing along the longitudinal axis to produce an elongated tubing having a secondary length greater than the primary length;
 - (d) restraining the elongated tubing to prevent the elongated tubing from longitudinally contracting during sintering;
 - (e) sintering the elongated tubing to produce a sintered tubing having a length substantially equivalent to the secondary length;

- 45 -

(f) radially expanding the sintered tubing to produce radially expanded tubing have an expanded inner diameter greater than the primary inner diameter; and

5 (g) sintering the radially expanded tubing to contract the radially expanded tubing and produce a tubing having an inner diameter substantially equivalent to the primary inner diameter.

3. The method of claim 1 or 2 including the additional step after step (g) of longitudinally 10 stretching the sintered radially expanded tubing.

4. The method of claim 1 or 2 including the step, between steps (f) and (g), of restraining the ends of the radially expanded tubing to maintain the length of the radially expanded tubing when the radially expanded 15 tubing is sintered.

5. A tube-form medical implant of porous material comprising crystalline polytetrafluoroethylene (PTFE) polymer, which material has a microstructure of nodes interconnected by fibrils in the form of a PTFE tube in a 20 pre-dilated and contracted diameter state as a result of radial expansion of a longitudinally expanded, sintered PTFE tube, followed by contraction produced by re-sintering, the tube-form implant being expandable in use from the contracted diameter to a substantially larger 25 implantation diameter by application of radial force.

6. An implant in accordance with claim 5 formed from an extruded tube having an original inner diameter, in which the pre-dilation increased the inner diameter to at least two times the original inner diameter.

- 46 -

7. An implant in accordance with claim 5 formed from an extruded tube having an original inner diameter, in which the pre-dilation increased the inner diameter to at least three times the original inner diameter.

5 8. An implant in accordance with claim 5 formed from an extruded tube having an original inner diameter, in which the pre-dilation increased the inner diameter to at least four times the original inner diameter.

9. An implant in accordance with claim 5 formed
10 from an extruded tube having an original inner diameter, in which the pre-dilation increased the inner diameter to at least five times the original inner diameter.

10. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a Radial
15 Expansion Coefficient (REC) of less than 2.0.

11. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a Radial Expansion Coefficient (REC) of less than 1.7.

12. A tube-form medical implant in accordance
20 with claim 5 wherein the tube-form implant has a Radial Expansion Coefficient (REC) of less than 1.5.

13. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a Radial Expansion Coefficient (REC) of less than 1.0.

25 14. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a Radial Expansion Ratio (RER) of less than 30.

- 47 -

15. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a Radial Expansion Ratio (RER) of less than 20.

16. A tube-form medical implant in accordance 5 with claim 5 wherein the tube-form implant has a Radial Expansion Ratio (RER) of less than 10.

17. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a Radial Expansion Ratio (RER) of less than 5.

10 18. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has a ratio of Reduction Ratio (RR) to Lubricant Level (LL) of less than 5.

15 19. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has the characteristic of maintaining its structural integrity until the tube-form implant is radially expanded by more than 50%.

20 20. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has the characteristic of maintaining its structural integrity until the tube-form implant is radially expanded by more than 75%.

25 21. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has the characteristic of maintaining its structural integrity until the tube-form implant is radially expanded by more than 100%.

- 48 -

22. A tube-form medical implant in accordance with claim 5 wherein the tube-form implant has the characteristic of maintaining its structural integrity until the tube-form implant is radially expanded by more than 150%.

23. An expandable tubular medical implant comprising porous material of crystalline polytetrafluoroethylene polymer having a microstructure of nodes interconnected by fibrils, the tubular implant being permanently, radially expandable from a small delivery diameter, which is of low profile suitable for delivery to an implantation site inside a blood vessel, to a more than 50% larger implantation diameter, which is suitable for implantation inside a blood vessel, by application of outward radial force, the tubular medical implant, after expansion to the implantation diameter, substantially retaining its expanded size, tensile strength, and structural integrity so that increase in the outward radial force is required before further radial expansion can occur.

24. A readily dilatable tube having a low profile delivery diameter, the tube constructed as a tubular implant for use in concentric relationship with an expandable stent, the tube, upon expansion by more than 50% to an implantation diameter, retaining structural integrity and substantial strength, the tube comprising a tube of expanded polytetrafluoroethylene (PTFE) in a pre-dilated and contracted diameter state as a result of radial expansion of a longitudinally expanded, sintered PTFE tube, followed by contraction produced by re-sintering.

- 49 -

25. The tubular implant of claim 23 or 24 wherein the tubular implant has the characteristic of substantially retaining its expanded size, structural integrity, and substantial tensile strength when expanded 5 200% beyond its delivery diameter so that increase in outward radial force is required before further radial expansion can occur.

26. The expandable tubular implant of claim 5, 23, or 24 in combination with an endovascular stent.

10 27. The expandable tubular implant of claim 5, 23, or 24 in the form of a liner for an endovascular stent.

28. The expandable tubular implant of claim 5, 23, or 24 in the form of a cover for an endovascular 15 stent.

29. The expandable tubular implant of claim 5, 23, or 24 having the characteristic of being expandable by an angioplasty balloon catheter at a pressure of about 5 to 15 atmospheres.

20 30. The expandable tubular implant of claim 5, 23, or 24 having the characteristic that its longitudinal length does not substantially change as a result of radial expansion.

31. A medical implant in accordance with claim 5, 25 23, or 24 having the characteristic of maintaining its structural integrity when expanded by 50% or more so that increase in the radial force is required before further expansion can occur.

- 50 -

32. A medical implant in accordance with claim 5, 23, or 24 having the characteristic of maintaining its structural integrity when expanded by 100% or more so that increase in the radial force is required before 5 further expansion can occur.

33. A medical implant in accordance with claim 5, 23, or 24 having the characteristic of maintaining its structural integrity when expanded by 200% or more so that increase in the radial force is required before 10 further expansion can occur.

34. A medical implant in accordance with claim 5, 23, or 24 having the characteristic of maintaining its structural integrity when expanded by 300% or more so that increase in the radial force is required before 15 further expansion can occur.

35. A medical implant in accordance with claim 5, 23, or 24 having the characteristic of maintaining its structural integrity when expanded by 400% or more so that increase in the radial force is required before 20 further expansion can occur.

36. An expandable endovascular stent having a contracted diameter state with an outer diameter suitable for delivery through the vasculature of a patient to a desired site and an expanded diameter state with an outer 25 diameter suitable for supporting a blood vessel at the desired site, the stent comprising

a tubular medical implant in accordance with claim 5, 23, or 24 having an interior wall surface and an exterior wall surface, and

30 at least one tubular, radially expandable support structure coupled to the tubular medical implant, the

- 51 -

support structure having an interior wall surface and an exterior wall surface.

37. The expandable endovascular stent of claim 36 wherein the tubular medical implant is disposed on the 5 exterior wall surface of the at least one support structure.

38. The expandable endovascular stent of claim 36 wherein the tubular medical implant has first and second ends, there being two of the support structures disposed 10 within the interior wall surface of the medical implant at first and second ends thereof, respectively.

39. The expandable endovascular stent of claim 36 wherein the tubular medical implant is disposed within the interior wall surface of the at least one support 15 structure.

40. The expandable endovascular stent of claim 39 wherein an extension of the tubular medical implant wraps around an end of the at least one support structure, from the interior wall surface to the exterior wall surface of 20 the support structure.

41. The expandable endovascular stent of claim 36 wherein the first tubular medical implant is disposed within the interior wall surface of the at least one support structure, and further comprising a second 25 tubular implant in accordance with claim 4 disposed about the exterior wall surface of the at least one support structure.

42. The endovascular stent of any one of claims 36-41 wherein the at least one radially expandable

- 52 -

support structure retains its shape upon expansion to the expanded diameter state as a result of deformation beyond the elastic limit of the material forming the support structure.


5 43. The endovascular stent of any one of claims
36-41 wherein the at least one or more radially
expandable support structure is radially self-expandable
to the expanded diameter state.

10 44. The endovascular stent of claim 43 wherein
the at least one radially expandable support structure is
self-expanding as a result of thermal activation.

45. The endovascular stent of any one of claims
36-44 wherein the at least one support structure is
formed from stainless steel or nitinol.

15 46. The endovascular stent of any one of claims
36-45 wherein the tubular medical implant is coated with
a pharmacological agent.

1/3

**FIG. 1**

2/3




FIG. 2




FIG. 2A




FIG. 3




FIG. 3A




FIG. 4










FIG. 4A

3/3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/07326

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61M 29/00;A61F 2/06; B29C 67/02
US CL : 623/1, 900; 606/198; 264/119, 127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 623/1, 900; 606/198; 264/119, 127

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A, 5,071,609 (TU ET AL) 10 December 1991, see entire document.	5-23,25
---		-----
Y		29-35
A	US, A, 4,110,392 (YAMAZAKI) 29 August 1978.	
A	US, A, 5,061,276 (TU ET AL) 29 October 1991.	
A,P	US, A, 5,383,928 (SCOTT ET AL) 24 January 1995.	
A	US, A, 5,217,483 (TOWER) 08 June 1993.	

Further documents are listed in the continuation of Box C.

See patent family annex.

•	Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 AUGUST 1995

Date of mailing of the international search report

20 SEP 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARY LYNN F. THEISEN

Telephone No. (703) 305-0651